share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  07/05 16:17
Moomoo AI 已提取核心信息
On July 3, 2024, SeaStar Medical Holding Corporation notified The Nasdaq Stock Market LLC of a possible violation of Nasdaq Listing Rule 5635(d)(2) concerning the issuance of shares without shareholder approval. The issue arose from the conversion of convertible notes and exercise of warrants issued to an institutional investor. These financial instruments were part of a Securities Purchase Agreement from March 15, 2023, which was approved by shareholders at the Annual Meeting on June 28, 2023. Amendments to the agreement on August 7, 2023, and December 11, 2023, involved additional convertible notes and warrants, with adjustments to conversion and exercise prices. SeaStar Medical has requested Nasdaq to review the transactions for compliance and has committed to adhering to Nasdaq's shareholder approval requirements for future securities issuances.
On July 3, 2024, SeaStar Medical Holding Corporation notified The Nasdaq Stock Market LLC of a possible violation of Nasdaq Listing Rule 5635(d)(2) concerning the issuance of shares without shareholder approval. The issue arose from the conversion of convertible notes and exercise of warrants issued to an institutional investor. These financial instruments were part of a Securities Purchase Agreement from March 15, 2023, which was approved by shareholders at the Annual Meeting on June 28, 2023. Amendments to the agreement on August 7, 2023, and December 11, 2023, involved additional convertible notes and warrants, with adjustments to conversion and exercise prices. SeaStar Medical has requested Nasdaq to review the transactions for compliance and has committed to adhering to Nasdaq's shareholder approval requirements for future securities issuances.
2024年7月3日,SeaStar Medical Holding Corporation通知纳斯达克证券交易所可能存在违反纳斯达克交易规则5635(d)(2)的情况,涉及未经股东批准发行股份的问题。这一问题源于可转换债券的转换以及发给机构投资者的权证的行使。这些金融工具是2023年3月15日证券购买协议的一部分,该协议已经在2023年6月28日的年度股东大会上获得股东批准。协议于2023年8月7日和2023年12月11日进行了修订,涉及到额外的可转换债券和权证,转换和行使价格有所调整。SeaStar Medical已要求纳斯达克审核交易是否符合规定,并承诺未来证券发行将遵守纳斯达克股东批准要求。
2024年7月3日,SeaStar Medical Holding Corporation通知纳斯达克证券交易所可能存在违反纳斯达克交易规则5635(d)(2)的情况,涉及未经股东批准发行股份的问题。这一问题源于可转换债券的转换以及发给机构投资者的权证的行使。这些金融工具是2023年3月15日证券购买协议的一部分,该协议已经在2023年6月28日的年度股东大会上获得股东批准。协议于2023年8月7日和2023年12月11日进行了修订,涉及到额外的可转换债券和权证,转换和行使价格有所调整。SeaStar Medical已要求纳斯达克审核交易是否符合规定,并承诺未来证券发行将遵守纳斯达克股东批准要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息